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P53 inactivation is often observed in Burkitt’s lymphoma (BL) cells due to mutations in the p53 gene or overexpression of its
negative regulator, murine double minute-2 (MDM2). This event is now considered an essential part of the oncogenic process.
Epstein–Barrvirus(EBV)isstronglyassociatedwithBLandisacofactorinitsdevelopment.Wepreviouslyshowedthatnutlin-3,
an antagonist of MDM2, activates the p53 pathway in BL cell lines harboring wild-type p53. However, nutlin-3 strongly induced
apoptosis inEBV ( ) orlatency IEBV (þ)cells, whereaslatency IIIEBV (þ)cellsweremuch moreresistant. We show here that
this resistance to apoptosis is also observed in latency III EBV (þ) lymphoblastoid cell lines. We also show that, in latency III
EBV (þ) cells, B-cell lymphona 2 (Bcl-2) is selectively overproduced and interacts with Bcl-2-associated X protein (Bax),
preventing its activation. The treatment of these cells with the Bcl-2-homology domain 3 mimetic ABT-737 disrupts Bax/Bcl-2
interactionandallowsBaxactivationbynutlin-3.Furthermore,treatment withthese twocompoundsstronglyinducesapoptosis.
Thus, a combination of Mdm2 and Bcl-2 inhibitors might be a useful anti-cancer strategy for diseases linked to EBV infection.
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The p53 tumor suppressor is a transcription factor that is
activated in response to DNA or cell damage, such as
oncogene activation, radiation, mitotic stress, ribosomal
stress or chemical challenge.
1 When activated, p53 has a
key role in protecting against tumor development, by inducing
cell cycle arrest or apoptosis.
2 This physiological function of
p53 is frequently altered in malignant cells, through mutation,
cytoplasmic sequestration, interaction with viral oncoproteins
or an increase in interactions with its main cellular regulator
murine double minute-2 (MDM2).
3 MDM2 is an E3 ubiquitin
ligase that binds p53 and induces its ubiquitin-dependent
degradation.
4MDM2 also inhibitsthe transcriptional activityof
p53 through direct protein–protein interactions.
5 MDM2 over-
production, leading to p53 inactivation, has been observed in
various types of cancer.
6,7 Given the key role of p53 in
determining cell fate, several strategies for disrupting the
p53–MDM2 interaction have been explored.
8,9 Potent, stable
and selective small-molecule antagonists of MDM2 have
recently been synthesized. These molecules include nutlins,
cis-imidazoline compounds that act by binding to the p53
pocket of MDM2, thereby overcoming the inhibitory effects of
thismoleculeandinducingthereleaseandactivationofp53.
10
Nutlin treatment has been shown to enhance apoptosis
in various tumor cells in vitro,
11,12 to inhibit tumor growth
in vivo
10,13 and to act in synergy with genotoxic drugs or
irradiation in cancer therapy (reviewed in Vassilev
14).
The anti-cancer activity of p53 results principally from the
ability of this molecule to induce apoptosis through the
intrinsic mitochondrial pathway.
15 The crucial event in the
initiation of this pathway is mitochondrial outer membrane
permeabilization (MOMP), leading to the release of signaling
molecules from the intermembrane space into the cytosol.
16
This process is controlled by members of the B-cell lymphoma 2
(Bcl-2) protein family.
17 This family has pro-apoptotic mem-
bers, classiﬁed into ‘effectors’ (Bcl-2-associated X protein
(Bax) and Bak), which participate directly in membrane
permeabilization, and ‘Bcl-2-homology domain 3 (BH3)-only
members’ (Puma, Noxa, Bad, Bim and Bid), which act as
‘direct activators’ or ‘sensitizers’ of the apoptotic pathway.
18
However, this family also has anti-apoptotic members, such
as Bcl-2, B-cell lymphoma-extra large (Bcl-xL) and myeloid
cell factor-1 (Mcl-1), which antagonize MOMP. The levels of
the pro-apoptotic Bcl-2 family proteins Bax, Noxa, Bid and
Puma are directly regulated by p53.
19
The p53 pathway is frequently disrupted in Burkitt’s
lymphoma (BL) cells, and this disruption is now considered
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20 In a
previous study, we therefore investigated the consequences
of activating wt p53 and determined whether Epstein–Barr
virus (EBV) infection of the cells had an effect on these
consequences.
21 The EBV genome is present in the vast
majority of BL cases. The virus remains latent in infected
tumor cells, producing only a very small number of viral
proteins.
22 Most EBV-infected BL cells harbor the latency I
phenotype (Epstein–Barr nuclear antigen 1 (EBNA1) is the
only viral protein produced). However, cases with the latency
III proﬁle (all latent EBV proteins are produced: EBNA1, 2, 3a,
3b, 3c, EBNA leader protein, latent membrane protein 1
(LMP1) and 2 (LMP2)) have also been identiﬁed.
23 Latent
EBV does not speciﬁcally target p53, but it nonetheless
interferes with cell cycle checkpoints regulated by p53 in the
G1/S and G2/M phases
24 and modulates p53-induced
apoptosis.
25 We have shown that, regardless of EBV status,
the treatment of BL cells with nutlin-3 induces p53 activation,
as shown by the induction of p21
WAF1 MDM2 and Bax.
However, although nutlin-3-treated EBV ( ) BL cells display
massive apoptosis, latency III EBV (þ) cells are much more
resistant.
21
In this study, we investigated the mechanism responsible
for the resistance to p53-mediated apoptosis induced by EBV
in lymphoid cells. We analyzed two types of EBV (þ) latency
III cells: BL cells and lymphoblastoid cell lines (LCLs), a
recognized model for the study of post-transplantation
lymphoproliferative disorders. Both types of cell were found
to be more resistant to treatment with nutlin-3 than EBV ( )
cells. In EBV ( ) cells, Bax was activated by nutlin-3
treatment, promoting apoptosis. By contrast, in EBV (þ)
latency III cells, Bax accumulated in mitochondria but was
poorly activated by nutlin-3. Our ﬁndings indicate that Bcl-2 is
selectively overproduced in these cells and forms stable
complexes with Bax. Treatment with nutlin-3 has no sig-
niﬁcant impact on these complexes. Finally, we also demon-
strated that ABT-737, a potent and selective small molecule
that binds and antagonizes Bcl-xl, Bcl-2 and Bcl-w, sensitizes
EBV (þ) latency III cells to nutlin-3 treatment.
Results
Latency III EBV (þ) cells are more resistant than EBV ( )
cells to p53-dependent apoptosis. We have previously
shown that, in BL cell lines, the induction of apoptosis by
nutlin-3 depends on the EBV status of the cells: EBV ( ) and
EBV (þ) latency I cells are highly sensitive to this antagonist
of MDM2, whereas EBV (þ) latency III cells are much more
resistant.
21 We investigated whether other EBV (þ) latency
III cells were also resistant to p53-dependent apoptosis by
evaluating the response to nutlin-3 treatment in LCLs. All cell
lines were treated with 10mM nutlin-3 for 24h and apoptosis
was assessed by ﬂow cytometry after labeling the cells with
annexin-V-FITC and propidium iodide (PI). Nutlin-3 induced
slightly higher levels of apoptosis in LCL (52±10%, 49±4%,
48±7% apoptotic cells for RPMI8866, Priess and Remb1
cells, respectively) than in latency III BL cell lines (40±4%,
18±5%, 36±2%, for BL2/B95, Seraphina and LY47 cells,
respectively) but these levels of apoptosis remained lower
than those in EBV ( ) BL cell lines (76±4%, 95±4% for BL2
and BL28 cells, respectively; Figure 1a).
Wecharacterizedtheapoptoticcelldeathinducedbynutlin-
3 in more detail by measuring the loss of mitochondrial
membrane potential (DCm) by ﬂow cytometry with the
carbocyanine dye 30-dihexyloxacarbocyanine iodide
(DiOC6(3)). Loss of DCm occurs early in apoptosis and was
therefore measured after 16h of treatment with nutlin-3. In
EBV ( ) BL cells treated with nutlin-3, mitochondrial
depolarization was observed in 53±6 % of BL2 cells and
89±5% of BL28 cells (Figure 1b). By contrast, in EBV (þ)
latency III cells (BL and LCL), the loss of DCm was much
milder, with 25±2%, 9±3%, 5±4%, 19±4%, 22±1%,
23±2 % mitochondrial depolarization in BL2/B95, Seraphina,
LY47, RPMI8866, Priess and Remb1 cells, respectively.
We then carried outwestern blotting to assessthe cleavage
of poly (ADP-ribose) polymerase (PARP), a DNA repair
enzyme directly targeted by caspase-3 (cysteinyl aspartate-
speciﬁc protease-3). After 7h of treatment with nutlin-3, the
85kDaPARPcleavageproductwasobserved inEBV( )BL2
and BL28 cell extracts, whereas no cleavage was observed in
EBV (þ) BL and LCL extracts, except for Remb1 cells, in
which low levels of cleavage were detected (Figure 1c). After
24h of treatment, PARP was almost totally (BL2) or totally
(BL28) cleaved in EBV ( ) cells. By contrast, in EBV (þ)
cells, PARP cleavage occurred either at very low rates
(BL2/B95, RPMI8866, Priess and Remb1 cells) or not at all
(Seraphina and LY47 cells). Thus, both BL and LCL latency III
EBV (þ) cells are more resistant than EBV ( ) cells to
p53-mediated apoptosis.
The activation of p53 increases Bax levels similarly in
EBV ( ) and EBV (þ) cell lines. In susceptible EBV ( )B L
cells, nutlin-3-induced apoptosis involves permeabilization of
the mitochondrial outer membrane. This mechanism is
generally controlled and mediated by Bcl-2 family proteins.
The pro-apoptotic protein Bax, encoded by a p53 target
gene, is one member of this family. We showed in a previous
study that nutlin-3 activated the p53 pathway similarly in all
BL cell lines.
21 In this study, we measured the accumulation
of Bax in both EBV ( ) BL cell lines and EBV (þ) latency III
BL and LCL treated with nutlin-3 for various periods of time
(3, 7 or 24h). Western blot analysis was carried out to
determine the levels of p53 (as a control of its activation) and
of Bax. Bax-speciﬁc bands were quantiﬁed by densitometry
and normalized with respect to b-actin levels. In all cell lines,
treatment with nutlin-3 induced a gradual increase in Bax
levels until 24h of treatment (Figure 2). These results are
consistent with our previous ﬁndings and conﬁrm that the
accumulation of Bax in response to p53 activation is not
correlated with the EBV status of the cells and that the
resistance of EBV (þ) cells to apoptosis does not result from
a defect in Bax accumulation.
Following p53 activation, Bax accumulates in the
mitochondria of latency III EBV (þ) cells but is not
activated. For Bax to be active, it must be translocated from
the cytosol (where it is found in healthy cells) to the outer
mitochondrial membrane. The redistribution of Bax was
assessed by western blot analysis of the mitochondrial and
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Cell Death and Diseasecytosolic fractions of untreated cells and of cells treated with
nutlin-3 for 24h (Figure 3a). Fractionation quality was
checked by probing blots with antibodies recognizing
proteins known to be localized to mitochondria (Bcl-2) or
the cytosol (vinculin). Bax-speciﬁc bands were then
quantiﬁed by densitometry and the results were normalized
with respect to Bcl-2 or vinculin levels. In EBV ( ) BL cells,
nutlin-3 treatment either strongly decreased the amount of
Bax in the cytosolic fractions (BL2) or resulted in this protein
being undetectable (BL28) in these fractions, whereas Bax
levels in the mitochondrial fractions clearly increased. By
contrast, in EBV (þ) cell lines (BL and LCL), Bax
accumulated in both the cytosolic and mitochondrial
fractions after treatment with nutlin-3.
We investigated whether the Bax accumulating in the
mitochondria was in the activated form by labeling cells with
the 6A7 conformation-speciﬁc Bax mAb (Figure 3b). This
antibody recognizes an N-terminal epitope of Bax that is
occluded in the inactive form of the protein but exposed after
the activation and insertion of the protein into membranes.
26
After treatment with nutlin-3, 52% of EBV ( ) BL2 cells were
positive for 6A7 labeling (mean ﬂuorescence intensity (MFI):
105 versus 48 for control), whereas latency III EBV (þ) cells
were only weakly stained (2% (MFI: 38 versus 36), 25% (MFI:
66versus39)and32%(MFI:68versus28)forLY47,BL2/B95
and Remb1 cells, respectively).
To conﬁrm that the activation of Bax is involved in nutlin-3-
mediated apoptosis of BL2 cells, we next inhibited the
production of this protein with a speciﬁc small-interfering
RNA, treated the cells with nutlin-3 and then measured
apoptosis levels by assessing PARP cleavage on western
blots. In BL2 cells with low levels of Bax, lower levels of PARP
cleavage were observed than in controls cells (Supplemen-
tary Figure 1). These data show that, in EBV ( ) cells treated
with nutlin-3, Bax accumulates in mitochondria in its activated
form and takes part in the apoptotic process. By contrast, in
EBV (þ) latency III cells, most of the Bax accumulating in the
mitochondria is not in the active conformation.
Bcl-2 is overproduced in latency III EBV (þ) cells. At
least three EBV-encoded proteins (LMP1, LMP2A and
EBNA2) have been shown to induce the upregulation of
various anti-apoptotic Bcl-2 family members able to
sequester Bax.
27–29 We therefore carried out western
blotting to evaluate the endogenous levels of these anti-
apoptotic proteins (Bcl-2, Bcl-xL and Mcl-1) in our cell lines
(Figure 4). There was no direct correlation between the EBV
status of the various cell lines and basal levels of Bcl-xL or
Mcl-1. By contrast, a strong correlation was observed
between basal levels of Bcl-2 and EBV status: all latency
III EBV (þ) cells contained high levels of Bcl-2, whereas
EBV ( ) cells had low levels of this protein. To conﬁrm that
high levels of Bcl-2 were correlated with LMP1 expression,
28
we also assessed the level of this viral protein. Large
amounts of LMP1 were observed in all EBV (þ) cell lines
except BL2/B95, which had only low levels of this protein. As
LMP1 has also been shown to induce the downregulation of
Bax,
30 we determined endogenous Bax levels in our various
cell lines. No correlation was observed between the EBV
status and Bax levels.
Figure1 Effectofnutlin-3treatmentontheinductionofapoptosisinEpstein–Barrvirus(EBV)( ),EBV(þ)Burkitt’slymphoma(BL)andlymphoblastoidcelllines(LCLs).
(a) Cells were treated with 10mM nutlin-3 or with the solvent dimethyl sulfoxide for 24h. The cells were labeled with annexin V-FITC and PI and analyzed with a FACSCalibur
ﬂow cytometer to determine the percentage of cells that were apoptotic. The values presented (means±s.d.) are from three independent experiments. (b) Cells were treated
with 10mM nutlin-3 or the solvent dimethyl sulfoxide for 16h. The cells were stained with DIOC6(3) and analyzed on a FACSCalibur ﬂow cytometer. DiOC6(3) stains
mitochondria in a potential-dependent fashion. Cells with a low DCm are therefore only weakly ﬂuorescent, and are described as ‘DiOC6(3) negative’. The values presented
(means±s.d.) are from three independent experiments. (c) Cells were treated with 10mM nutlin-3 for the indicated periods of time. Apoptosis levels were determined by
assessing polyadenosine diphosphate-ribose polymerase (PARP) cleavage on western blots. Results are representative of at least three independent experiments
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Cell Death and DiseaseBcl-2 interacts with Bax in latency III EBV (þ) cells, but
not in EBV ( ) cells. We investigated the role of Bcl-2 in the
resistance to apoptosis observed in latency III EBV (þ) cells
by studying the interactions between Bax and Bcl-2. BL2
EBV ( ) cells and BL2/B95 EBV (þ) cells (which differ only
in terms of their EBV status) were left untreated or treated
with nutlin-3 for 7h. Proteins were then extracted and
immunoprecipitation was carried out with an anti-Bax pAb.
The immunoprecipitates were then probed for Bax and Bcl-2
(Figure 5). These western blots showed that treatment with
nutlin-3 induced a stronger accumulation of Bax in BL2 than
in BL2/B95 cells, but that Bcl-2 was coprecipitated with Bax
only in BL2/B95 cells, with nutlin-3 treatment having no
signiﬁcant impact on this co-immunoprecipitation. Thus, in
EBV (þ) latency III cells, Bax and Bcl-2 form stable
complexes that may be at least partly responsible for the
resistance to apoptosis.
An inhibitor of Bcl-2 disrupts the interactions between
Bax and Bcl-2 and allows Bax activation in BL2/B95 EBV
(þ) cells treated with nutlin-3. We investigated the
involvement of interactions between Bax and Bcl-2 in
resistance to nutlin-3-induced apoptosis using ABT-737, a
BH3 mimetic that antagonizes pro-survival members of the
Bcl-2 family, promoting the release of Bax.
31 We ﬁrst
investigated the effect of this Bcl-2 inhibitor on Bax/Bcl-2
interaction. BL2/B95 EBV (þ) cells were treated for 1h with
ABT-737 (10mM), incubated with nutlin-3 for 7h and protein
extracts were prepared. We then assessed Bax and Bcl-2
levels by western blotting and interaction between these two
molecules by co-immunoprecipitation. Treatment with ABT-737
had no effect on Bcl-2 or Bax levels (Figure 6a), but abolished
the co-immunoprecipitation of Bax with Bcl-2, in both untreated
cells and cells treated with nutlin-3 (Figure 6b).
We also evaluated the effect of treatment with ABT-737 on
the distribution of Bax in untreated cells and cells treated with
nutlin-3. ABT-737 decreased the accumulation of Bax in
the cytosol induced by nutlin-3 alone and concomitantly
increased the level of Bax in the mitochondria (Figure 6c). We
investigated whether the Bax accumulating in the mitochon-
driawasintheactivatedformbylabelingthecellswiththe6A7
conformation-speciﬁc Bax mAb (Figure 6d). After treatment
withABT-737aloneornutlin-3alone,10%(MFI:39versus31)
and 23% (MFI: 62) of BL2/B95 cells, respectively, were
weakly positive for 6A7 labeling, whereas when the two
compounds were used in combination, 41% (MFI: 74) of the
cells were strongly labeled with the 6A7mAb. Thus, a
combined treatment with ABT-737 and nutlin-3 induces the
release of Bax from the Bax/Bcl-2 complexes and its
activation in mitochondria.
An inhibitor of Bcl-2 restores the susceptibility
of latency III EBV (þ) cells to p53-dependent
apoptosis. We then used ﬂow cytometry to determine
whether treatment with ABT-737 sensitized the EBV (þ)
latency III BL and LCL cells to nutlin-3-induced apoptosis
(Figure 7a). Consistent with our previous observations,
treatment with nutlin-3 for 24h induced o50% apoptosis in
these cells. Treatment with ABT-737 (10mM) alone had no
cytotoxic effect on BL2/B95 and Seraphina cells but induced
42±7% apoptosis in LY47 cells. An even stronger effect was
observed in LCL cells, in which treatment with 10mM ABT-
737 for 24h induced 470% apoptosis (data not shown). In
these cell lines, we therefore decreased the concentration of
ABT-737 used to reduce its cytotoxic effect. Treatment with
0.25mM ABT-737 induced 32±8%, 47±3% and 39±2%
apoptosis in RPMI8866, Priess and Remb1 cells, respec-
tively. When the two drugs were used in combination, a
synergic effect on the induction of apoptosis was observed in
BL2/B95 and Seraphina cells (78±5% and 81±3%
apoptotic cells, respectively). In the other cell lines, no
synergy between ABT-737 and nutlin-3 was observed, these
Figure 2 Effect of nutlin-3 treatment on p53 and Bax levels in Burkitt’s lymphoma (BL) and lymphoblastoid cell lines (LCLs). Cells were treated with 10mM nutlin-3 for the
indicatedperiodsoftime.Thelevelsofp53andBaxproteinwereassessedbywesternblotanalysis.Fold-changevaluesforBaxversustheuntreatedcontrol(0h),normalized
with respect to b-actin levels are shown under the blots
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71±8%, 73±7% and 81±5% apoptosis in LY47,
RPMI8866, Priess and Remb1 cells, respectively). We also
evaluated the effect of nutlin-3 and ABT-737 on three cell
lines originating from the same individual: BL40, BL40/B95
and IARC 211. BL2 and BL2/B95 were used as controls.
Apoptosis was determined by assessing PARP cleavage on
western blots (Figure 7b). No cleavage of PARP was
Figure 3 Effectof nutlin-3 treatmenton Baxrelocalizationand activationin EBV( ) andEBV (þ)cells. (a) Cellswere treatedwith 10mM nutlin-3or thesolventdimethyl
sulfoxide for 24h. Cytosolic and mitochondrial fractions were analyzed by western blotting with an anti-Bax pAb. Vinculin and Bcl-2 were used as cytosolic and mitochondrial
markers, respectively. Fold-change values versus the untreated control (0h), after normalization with respect to vinculin or Bcl-2 protein levels, are shown under the blots.
Results are representative of three independent experiments. (b) BL2 EBV ( ) cells and BL2/B95, LY47 and Remb1 EBV (þ) cells were treated with 10mM nutlin-3 or the
solvent dimethyl sulfoxide for 24h. Cells were ﬁxed in 0.25% paraformaldehyde and labeled with a conformation-speciﬁc 6A7 Bax antibody, which recognizes only the active
conformation of the protein and Alexa 488-conjugated goat anti-mouse IgG. Cells were then analyzed with a FACSCalibur ﬂow cytometer
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BL2/B95 cells, whereas a strong or partial cleavage was
observed in BL40, BL40/B95 and IARC 211 cells. Treatment
with nutlin-3 alone induced strong (BL2) or complete (BL40)
cleavage of PARP in EBV ( ) cell lines, moderate cleavage
in BL2/B95 cells and almost no cleavage in BL40/B95 and
IARC 211 cells. As expected, treatment with both
compounds had an additive effect on cell viability and
PARP was totally cleaved in all cell lines.
Finally, as EBV reactivation might also reduce cell viability,
we tested the effects of nutlin-3 and ABT-737 on production of
the viral BZLF1 protein, a transcriptional activator that
mediates the transition between the latent and lytic cycles of
EBV. Except in LY47 cells, in which nutlin-3 slightly increased
the very low basal levels of BZLF1 protein, nutlin-3, ABT-737
and the combination of these two molecules were unable to
induce the production ofthis protein in any ofthe EBV (þ) cell
lines tested, (Supplementary Figure 2). Thus, a combined
treatment with ABT-737 and nutlin-3 efﬁciently induces the
apoptosis of latency III EBV (þ) cells producing large
amounts of Bcl-2 protein, without affecting the latent stage
of the virus.
Discussion
The activation of wt p53, or even the reactivation of mutant
p53, alone or in combination with cytotoxic agents (chemo-
therapy drugs or radiation) is now considered a promising
new approach for cancer treatment.
15,32 Various elements
must be considered during the development of such new
therapies, including the cellular context, which may greatly
modulate the consequences of p53 activation. In this study,
we showed that the type III latent EBV infection of lymphoid
cells does not prevent the p53 activation induced by an
inhibitor of Mdm2, but strongly decreases p53-induced
apoptosis. We also found that the activation of p53 induced
Bax accumulation similarly in all cell lines and that this pro-
apoptotic member of the Bcl-2 family was involved in the
apoptotic pathway in EBV ( ) cell lines. Bax is primarily a
cytosolic protein in healthy living cells. Following the induction
of apoptosis, it undergoes a conformational change and is
translocated to the mitochondria.
33 After nutlin-3 treatment,
Bax underwent conformational changes and relocalization in
EBV ( ) cells, whereas in EBV (þ) cells, it accumulated in
both the cytosol and the mitochondria but underwent no
conformational changes. Thus, the accumulation of Bax in the
mitochondria of EBV (þ) cells is not sufﬁcient to induce
apoptosis.
Several studies have shown that latent infection with EBV
protects cells from apoptosis. For example, the viral proteins
LMP1 and LMP2A have been shown to upregulate various
anti-apoptotic members of the Bcl-2 family by activating the
nuclear factor-k B (NFkB) pathway,
28 or to inhibit the
transcription of the pro-apoptotic Bax protein.
30 We deter-
minedtheendogenouslevelsofBax,Bcl-2,Bcl-xlandMcl-1in
our cell lines. Consistent with the results of Rowe et al.,
28 we
observed a strong correlation between basal Bcl-2 level and
EBV status: all latency III EBV (þ) cells had high levels of
Bcl-2, whereas EBV ( ) cells had low levels of this protein. By
contrast, Bax levels, similar to those of Bcl-xl and Mcl-1, were
variable in all cell lines, regardless of EBV status. It has been
reported that Bcl-2 inhibits both changes in the conformation
of the N-terminus of Bax and the translocation of Bax from the
cytosol to the mitochondria.
34,35 Our results are consistent
with these observations, as we observed no speciﬁc
translocation of Bax to the mitochondria after the treatment
with nutlin-3 of cells overproducing Bcl-2. We also showed
that Bcl-2 interacted with Bax in EBV (þ) cells, but not in EBV
( ) cells. This sequestration of Bax may account, at least in
part, for the resistance to nutlin-3 observed in EBV (þ)
latency III cells. Our results are also consistent with those of
Forte and Luftig,
36 who previously showed that, in LCL, nutlin-3
induced p53 activation and a moderate level of apoptosis
(around 40% of annexin-V (þ) cells after 48h of treatment),
whichwasenhancedbyprevioustreatmentofthecellswithan
inhibitor of NFkB activity. They showed that NFkB activity
controlledsteady-statelevelsofMDM2protein andconcluded
that the NFkB inhibitor sensitized cells to nutlin-3 by
decreasing MDM2 levels. However, as the upregulation of
Figure 4 Levels of Bcl-2 family members in EBV ( ) and EBV (þ) lymphoid
cell lines. Levels of the Bax, Bcl-2, Bcl-xl and Mcl-1 proteins as well as these of the
viral LMP1 protein were assessed by western blot analysis
Figure 5 Interaction of Bax with Bcl-2 in BL2 EBV ( ) and BL2/B95 EBV (þ)
cells untreated or treated with nutlin-3. Cells were treated with 10mM nutlin-3 or the
solvent dimethyl sulfoxide for 7h. Lysates were subjected to immunoprecipitation
withagarose-conjugatedanti-BaxpAb(IP)oragarose-conjugatedcontrolrabbitIgG
(IgG control) and then subjected to western blotting with an anti-Bcl-2mAb or an
anti-Bax pAb. As a control for protein levels before IP, a portion of cell lysate (input)
corresponding to 15% of the input for IP was also included in the western blot.
All results are representative of three independent experiments
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Cell Death and DiseaseFigure 6 Effect of a combination of nutlin-3 and ABT-737 in the EBV (þ) cell lines. BL2B95 EBV (þ) cells were or were not subjected to prior treatment with 10mM
ABT-737 for 1h, and were then treated with nutlin-3 for 7h. (a) The levels of Bcl-2 and Bax proteins were assessed by western blot analysis. (b) Lysates were subjected to
immunoprecipitation with agarose-conjugated anti-Bax pAb (IP) or agarose-conjugated control rabbit IgG (IgG control) and then subjected to western blotting with an anti-
Bcl-2mAb or an anti-BaxpAb. As a control for protein levels before IP,a portion of cell lysate(Input) correspondingto 15%of theinput for IP was also included in the western
blot.Allresultsarerepresentativeofthreeindependentexperiments.(c)BL2/B95EBV(þ)cellswereorwerenotsubjectedtopriortreatmentwith10mMABT-737for1hand
were then treated with nutlin-3 for the indicated periods of time. Cytosolic and mitochondrial fractions were analyzed by western blotting with an anti-Bax pAb. Vinculin and
Bcl-2 were used as cytosolic and mitochondrial markers, respectively. Fold-change values versus the untreated control (0h), after normalization with respect to the levels of
vinculin or Bcl-2 protein, are shown under the blots. The results shown are representative of three independent experiments. (d) BL2/B95 cells were or were not subjected to
priortreatmentwithABT-737for1handwerethenleftuntreatedortreatedwithnutlin-3for24h.Cellswereﬁxedin0.25%paraformaldehydeandlabeledwithaconformation-
speciﬁc 6A7 Bax antibody, which recognizes only the active conformation of the protein and Alexa 488-conjugated goat anti-mouse IgG. Cells were then analyzed with a
FACSCalibur ﬂow cytometer
Figure 7 Effect of a combination of nutlin-3 and ABT-737 on the induction of apoptosis in EBV (þ) Burkitt’s lymphoma (BL) and lymphoblastoid cell lines (LCL). (a) EBV
(þ) cell lines were or were not subjected to prior treatment with ABT-737 (BL2/B95, Seraphina, LY47: 10mM; 8866, Priess, Remb1: 0.25mM) for 1h and were then left
untreatedortreatedwithnutlin-3for24h.ThecellswerelabeledwithannexinV-FITCandPIandanalyzedwithaFACSCaliburﬂowcytometer,todeterminethepercentageof
cells that were apoptotic. The values presented (means±s.d.) are from three independent experiments. (b) Cell lines were treated as in (a) and apoptosis levels were
determined by assessing polyadenosine diphosphate-ribose polymerase (PARP) cleavage on western blots. Results are representative of at least three independent
experiments
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Cell Death and DiseaseBcl-2 in B cells containing LMP1 is due to NFkB activa-
tion,
28,37 it could also be deduced from their data that the
NFkB inhibitor sensitizes cells by decreasing Bcl-2 levels.
ABT-737 is a BH3 mimetic that efﬁciently antagonizes
various pro-survival members of Bcl-2 family and promotes
the release of Bax and Bak.
31 In latency III EBV (þ) cells, the
disruption of Bax/Bcl-2 interaction by treatment with ABT-737
before nutlin-3 treatmentpromotedtherelocalization ofBax to
the mitochondria and its activation. Treatment with these two
compoundsalsostronglyinducedtheapoptosisofthesecells.
The combined inhibition of the MDM2 and Bcl-2 proteins has
been reported to strongly induce apoptosis in acute myelo-
genous leukemia cells overproducing Bcl-2
38 and in tumors
(including BL) in which Hdmx limits the p53 activation induced
by nutlin-3.
39 Combined treatment with nutlin-3 and an
inhibitor of the anti-apoptotic members of the Bcl-2 family,
such as ABT-737, may therefore constitute an attractive new
treatment strategy for tumors harboring wild-type p53 but with
defects in the p53-induced apoptotic pathway. In vivo studies
in murine models are now required to evaluate the effects of
this combined treatment in terms of side effects and tumor
regression and to compare these effects with those of
conventional chemotherapy.
Concerning latency III EBV (þ) cells, it will also be
interesting to use in vivo models to assess the efﬁciency of
ABT-737 alone, as we found that, even at very low doses, this
compound promoted apoptosis in LCL cells. This treatment
may be particularly beneﬁcial in patients with EBV (þ) post-
transplant lymphoproliferative disorder or nasopharyngeal
carcinoma, because both these types of tumor overproduce
Bcl-2 or Bcl-xL.
40
Materials and Methods
Cell lines. All BL cell lines were originally established from endemic or sporadic
cases of BL. BL2, BL28, BL40, BL2/B95, BL40/B95 and LY47 were kindly provided
by the International Agency for Research on Cancer (IARC, Lyon); Seraphina cells
wereprovidedbyProfessorGKlein(Stockholm);BL2/B95andBL40/B95cellswere
generated by stable infection of the original EBV ( ) BL2 and BL40 cells with the
B95-8 EBV strain. LCLs were obtained by the in vitro immortalization of normal B
lymphocytes. IARC 211 cells were established from the normal B lymphocytes of
patient BL40 and were obtained from IARC. Priess and Remb1 cells were kindly
provided by Dr JG Bodmer (London). These cell lines were cultured in RPMI 1640
medium (PAA) containing 2mM L-glutamine, 1mM sodium pyruvate, 20mM
glucose, 100U/ml penicillin and 100mg/ml streptomycin and supplemented with
10% heat-inactivated fetal calf serum.
Antibodies and reagents. Nutlin-3 was obtained from Cayman Chemical
(SPI-Bio,Montigny-le-Bretonneux,France);ABT-737waskindlyprovided byAbbott
Laboratories (Chicago, IL, USA).
PARP mAb (Ab-2, clone c-2-10) and anti-p53mAb (Ab-6, OP43) were
purchased from Calbiochem (Meudon, France). Anti-Bax pAb (N-20), anti-Bcl-
2mAb (clone 100), anti-Mcl-1mAb (clone 22), anti-Bcl-xl mAb (7B2.5) and
anti-BZLF1mAb (BZ1) were purchased from Santa Cruz Biotechnology Inc.
(Heidelberg, Germany). Anti-vinculin (clone VIN-11-5) and anti-b actin (clone
AC-74) mAbs were obtained from Sigma-Aldrich (Saint-Quentin Fallavier, France).
Anti-LMP1mAb (CS1-4) was obtained from Dako France SAS (Trappes, France).
Horseradish peroxidase (HRP)-conjugated rabbit anti-mouse IgG and
HRP-conjugated donkey anti-rabbit IgG for western blotting were purchased from
GE Healthcare (Velizy, France) and Jackson ImmunoResearch Laboratories
(Newmarket, UK), respectively.
Induction and quantiﬁcation of apoptosis. We treated 0.5 10
6
cells for various periods of time, at 371C, with nutlin-3 (10mM), ABT-737 (10mM)
or both these compounds. Cells were washed in PBS, resuspended in
annexin buffer (10mM HEPES/NaOH (pH 7.4), 150mM NaCl, 5mM KCl, 1mM
MgCl2, 1.8mM CaCl2) supplemented with 2.5mg/ml FITC-labeled annexin-V
(Roche Applied Science, Meylan, France) and incubated at room temperature for
10min. Cells were then washed, resuspended in annexin buffer supplemented with
PI (10mg/ml) and analyzed by ﬂow cytometry (n¼10000; FACSCalibur,
Becton-Dickinson, Pont-de-Claix, France). Annexin-V-positive cells (PI negative
or PI positive) were considered to be apoptotic.
Determination of mitochondrial membrane potential. After
treatment with nutlin-3, ABT-737 or both these compounds, for various periods of
time,DIOC6(3)wasadded(40nm)andcellswereincubatedforanadditional30min
at 371C. Cells were washed, resuspended in PBS supplemented with PI and
analyzed by ﬂow cytometry (n¼10000; FACSCalibur, Becton-Dickinson).
Intracellular labeling. Cells (2 10
6), either untreated or treated with
nutlin-3 (10mM), were ﬁxed by incubation in 0.25% paraformaldehyde for 20min at
room temperature. They were then washed twice and stained with primary
antibody (monoclonal anti-Bax antibody, clone 6A7, Sigma-Aldrich) in digitonin
(200mg/ml) for 30min at room temperature. The cells were then washed again with
PBS and incubated for 30min with goat anti-mouse IgG conjugated to Alexa 488
(GAM-Alexa-488, Molecular Probes, Leiden, The Netherlands). Samples were than
analyzedon a FACSCaliburﬂow cytometer.Cells labeled with GAM-Alexa-488 only
were used as a control.
Preparation of mitochondrial and cytosolic fractions. We
resuspended 2 10
6 cells in 100ml of ice-cold cell lysis and mitochondria intact
buffer (250mM sucrose, 70mM KCl, 200mg/ml digitonin) and incubated the
suspension at 41C for 5min. The samples were then centrifuged at 1000 g for
5min at 41C. The supernatants (cytosolic fractions) were recovered and stored at
 801C. The pellets were resuspended in 50ml of IP buffer (30mM Tris HCl
(pH 7.4), 150mM NaCl, 2mM EDTA, 2mM EGTA, 0.2% Triton 100, 0.3% NP40,
complete protease inhibitor cocktail) and incubated for 10min at 41C. The
suspension was then centrifuged at 10000 g for 10min at 41C and the
supernatants (mitochondrial fractions) were stored at  801C until use.
Immunoprecipitation. We subjected 5 10
6 cells to disruption by
sonication (10s on ice) in 1ml of CHAPS buffer (1% CHAPS, 1M Hepes, 5M
NaCl,completeproteaseinhibitorcocktail).Wemixedtheresultinglysateswith2mg
of agarose-conjugated rabbit anti-Bax pAb (clone N-20) or agarose-conjugated
control rabbit IgG pAb (Santa Cruz Biotechnology Inc.) and incubated the mixture
overnight at 41C, with end-over-end rotation. Immune complexes were washed
twice with ice-cold CHAPS buffer, twice with PBS and resuspended in loading
buffer. The samples were boiled for 5min and the proteins were separated by
electrophoresis in 4–12%Bis-Trisprecast gels (Invitrogen,CergyPontoise,France)
and analyzed by western blotting.
Western-blot analysis. A pellet containing 1 10
6 cells was solubilized by
incubation in ice-cold lysis buffer (150mM NaCl, 50mM Tris (pH 7.4), 5mM EDTA,
0.1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, complete protease inhibitor
cocktail)for10min.Sampleloadingbufferwasaddedandthemixturewasboiledfor
5min. Proteins were separated by electrophoresis in 12% polyacrylamide gels or
4–12% Bis-Tris precast gels (Invitrogen) and transferred to PVDF membranes
(Millipore, Molsheim, France). Blots were blocked by incubation overnight at 41Ci n
3% non-fat milk powder, 2% glycine in PBS and incubated for 1h at room
temperature with primary antibodies. The blots were then washed and incubated
with HRP-conjugated RAM-IgG or HRP-conjugated DAR-IgG. Antibody complexes
were detected by enhanced chemiluminescence (Millipore).
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